Conference reports

No increased risk of IRIS in people with low CD4 counts receiving raltegravir in the REALITY trial

Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated

Efavirenz might decrease effectiveness of the vaginal contraceptive ring

Switch to TAF appears safe and effective in adolescents: similar PK to adults

Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6

Twice-daily bictegravir does not overcome drug interaction with rifampicin

Reducing risk of myocardial infarction (MI) in HIV positive people

M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy

CROI 2018: second reports

Ibalizumab phase 3 results and susceptibility to drug-resistant HIV

Statin use might reduce risk of cancer in HIV positive people

Rate of bone loss on ART slows after the first year

Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN1 study

Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum

Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment

25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)

Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques

No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification

Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment

Twice-daily dolutegravir is effective and tolerable with rifampicin 

Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin

Efavirenz 400 mg can be given with anti-tuberculosis treatment 

Bictegravir at CROI 2018: switching studies and drug resistance analyses

PrEP at CROI 2018 (part 1): Access in Australia and the US

PrEP at CROI 2018 (part 2): Animal studies for future drugs

BHIVA best of CROI feedback workshops

CROI 2018 – highlights from the preliminary programme

16th European AIDS Conference (EACS 2017)

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

Dolutegravir-based dual therapy as switch option in multiple studies

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS

Dolutegravir use in pregnancy: results from small Belgian cohort

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

Updated European guidelines launched at EACS 2017

ABX464 nudges viral reservoir but not time to viral rebound

8th International Workshop on HIV & Ageing, 2–3 October 2017, New York

Selected webcasts from 8th HIV and ageing workshop

HIV and Ageing Workshop reports at

9th IAS Conference on HIV Science (IAS 2017)

Reassuring French data using raltegravir during pregnancy

Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

9th IAS Conference on HIV Science (IAS 2017)

Dual therapy with darunavir/r plus lamivudine as first-line ART

Dual therapy with dolutegravir plus lamivudine as first-line ART

Once-daily raltegravir: 96-week results from the ONCEMRK study

New IPERGAY analysis shows on-demand PrEP dosing works with less frequent sex

On-demand dosing for PrEP is highly effective in French expanded access programme

Psychological impact of PrEP: beyond efficacy and cost-effectiveness

Early ART and testing HIV negative with rapid HIV tests

Report from the IAS HIV Cure & Cancer Forum, 22–23 July 2017, Paris

9th IAS Conference on HIV Science (IAS 2017)

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Preliminary results on dolutegravir use in pregnancy are reassuring

Post navigation